CA-DEXCOM
2.2.2021 16:02:12 CET | Business Wire | Press release
DexCom, Inc . (NASDAQ:DXCM), the global leader in continuous glucose monitoring for people with diabetes, debuted today its first-ever Super Bowl commercial , starring multi-platinum recording artist, actor and philanthropist Nick Jonas, who was diagnosed with Type 1 diabetes at the age of 13. The ad, which will run during Super Bowl LV on Feb. 7, 2021, calls for better care for people with diabetes who are still painfully pricking their fingers to measure their glucose levels.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210202005348/en/
“Too many people with diabetes suffer through painful, antiquated fingerpricks because they don’t know a better way exists,” said Jonas. “I truly believe people with diabetes deserve the absolute best care, and that’s really the spirit of my first Super Bowl commercial. It means so much to me to bring this message of awareness and the need for improved CGM access to as many people with diabetes as possible.”
Tens of millions of people with diabetes around the world are still pricking their fingers, signaling a lack of awareness and the need to improve access for game changing CGM technology that has revolutionized diabetes management.
The Dexcom G6 CGM system uses a small wearable sensor and transmitter to measure and send real-time glucose values wirelessly to a compatible smart device or receiver,* eliminating the need for painful fingerpricks. † Dexcom CGM also displays trend arrows to show the speed and direction glucose levels are heading, making in-the-moment treatment decisions easier and helping people with diabetes avoid potentially dangerous high or low glucose events.‡
The ad, which will air at the end of the first quarter, shows how much various technologies have advanced over the last 40 years—contrasted by the realization that people with diabetes are still pricking their fingers to measure their glucose, a method invented in the 1970s.
“We are very excited to partner with Nick to shed light on technology that we know can significantly improve the lives of people with diabetes,” said Chad Patterson, senior vice president of global marketing for Dexcom. “People with diabetes deserve the best care, so along with leading diabetes advocacy groups, healthcare professionals and payers we are trying to increase awareness and improve access for CGM.”
As COVID-19 persists, Super Bowl parties are expected to look very different this year. For people with diabetes, a group at higher risk of COVID-19-related complications, social distancing and avoiding large gatherings is especially important. To help people feel less isolated on Super Bowl Sunday, Dexcom is giving fans the opportunity to “watch the game” with Nick Jonas through an interactive augmented reality experience.
Visit DexcomGameDay.com to see the commercial and find out how to watch the Super Bowl with Nick Jonas.
While the Super Bowl offers an enormous stage to launch this important conversation, Dexcom and Nick Jonas will be teaming up with leading diabetes nonprofits in the coming weeks to continue the discussion about better awareness, education and access for diabetes management technology. Organizations involved in this effort will include Beyond Type 1, the nonprofit co-founded by Nick, Children with Diabetes, College Diabetes Network, JDRF International and Taking Control of Your Diabetes.
To learn more about Dexcom CGM, visit Dexcom.com
About DexCom, Inc.
DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) products. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of patients, caregivers, and clinicians, Dexcom simplifies and improves diabetes management around the world. For more information, visit www.dexcom.com .
* For a list of compatible devices, visit www.dexcom.com/compatibility .
† If your glucose alerts and readings from the Dexcom G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
‡ The urgent low soon can warn you in advance of severe hypoglycemia—allowing you time to take appropriate action before it happens.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210202005348/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Announces Novel Quantum Error Correction Approach Toward Fault-Tolerant Quantum Computing9.6.2026 09:00:00 CEST | Press release
New approach delivers cutting edge performance, while significantly reducing hardware complexity IQM Quantum Computers, the global leader in superconducting quantum computers, has developed a novel quantum error-correcting code that achieves up to three orders of magnitude lower logical error rates than the surface code, also requiring up to eight times fewer physical qubits. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609533201/en/ IQM´s breakthrough technology, called barbell codes. Unlike many alternative high-performance quantum error-correction approaches, the new code also maintains a comparatively low hardware complexity, marking a significant advancement toward scalable fault-tolerant quantum computing. Quantum error correction remains one of the defining challenges in the race toward practical quantum computing. Errors introduced by noise must be corrected faster than they accumulate, a requirement that previo
Estonia Raises the Bar for Secure Digital Identity in Europe With New eID Cards Developed With Thales9.6.2026 09:00:00 CEST | Press release
The Estonian Police and Border Guard Board has begun the issuance of the country’s new electronic identity (eID) cards, marking a major milestone in the ongoing modernisation of Estonia’s renowned digital identity programme. This new generation of cards has been developed in partnership with Thales under an eight-year contract covering the full lifecycle of national identity documents - from issuance to personalisation -for residents, citizens, and specific groups such as diplomats or refugees. The advanced eID cards1 feature cutting-edge embedded security elements that can be upgraded to counter emerging cyber threats, ensuring citizens’ digital transactions remain protected over time. With increasing cyber risks and the rapid evolution of digital public services, Estonia is reinforcing the security, durability and adaptability of the documents that underpin its digital society: identity cards, residence permit cards, e-resident digital identity cards, diplomatic identity cards, certi
Longpoint Expands into Germany and the Netherlands, Targeting €400 Million of Infill Logistics Investment9.6.2026 09:00:00 CEST | Press release
Firm appoints Gijs Vissers and Benedict Stichel as country heads to lead growth across two key European logistics markets Longpoint Partners today announced its expansion into Germany and the Netherlands, extending its infill industrial strategy into two of Europe’s most supply-constrained logistics markets. The firm is establishing a presence in high-demand locations, including Düsseldorf, Frankfurt, and the Randstad, and plans to deploy approximately €400 million into logistics assets near major population centers and transportation corridors. “We are excited to expand Longpoint’s infill industrial strategy into Germany and the Netherlands,” said Dwight Angelini, Founding and Managing Partner of Longpoint Partners. “These are highly attractive logistics markets with strong fundamentals, limited supply, and a clear need for high-quality light industrial and logistics space. With Gijs and Benedict leading our local efforts, we have the market knowledge, relationships, and discipline to
ISO/TC 251 Recognizes Ampowr as the Only BESS Operator With a Fully Integrated ISO Stack9.6.2026 09:00:00 CEST | Press release
ISO/TC 251 and NEN, the Netherlands national standards body, profile Ampowr alongside Rijkswaterstaat, the US Army Corps of Engineers, Novo Nordisk and Veolia after an in-depth methodology interview with Executive Director Andrew Elwell. ISO/TC 251, the international technical committee that authors the ISO 55000 family of asset management standards, has published a case study profiling Ampowr's integrated certification methodology. Authored by NEN, the Dutch national standards body, the study is now publicly available in the ISO/TC 251 case studies library alongside profiles of Rijkswaterstaat, the US Army Corps of Engineers, Novo Nordisk, and Veolia. ISO/TC 251 approached Ampowr directly. NEN subsequently conducted an in-depth interview with Executive Director Andrew Elwell, examining how Ampowr operates its five certifications (ISO 9001, ISO 14001, ISO 45001, ISO 27001 and ISO 55001), as a single integrated system rather than separate compliance silos. "To our knowledge we are the o
Bial Reports Topline Results From ACTIVATE Phase 2b Study in GBA‑Associated Parkinson’s9.6.2026 08:00:00 CEST | Press release
Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, announced today that the Phase 2b ACTIVATE study of BIA 28-6156 (pariceract) in patients with Parkinson’s who have a pathogenic variant in the GBA1 gene (GBA-PD) did not meet its primary, nor the key secondary efficacy endpoints, meaning that BIA 28-6156 failed to slow the progression of GBA-PD versus placebo. BIA 28-6156 proved to be generally well tolerated in the study, with no unexpected safety concerns arising. While the study data provide valuable scientific information and contribute to a broader understanding of Parkinson’s biology, BIA 28-6156 did not demonstrate significant differentiation from placebo on the primary or key secondary endpoints measured. Based on the lack of demonstrated efficacy in this study, Bial has made the decision to discontinue further development of BIA 28-6156 for this indication. “We are disappointed with the outcome of the Phase 2b ACTIVATE study, as th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom